Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.
Saved in:
| Title: | Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials. |
|---|---|
| Authors: | Giovannoni G; Queen Mary University of London, London, UK., Kappos L; Research Center for Clinical Neuroimmunology and Neuroscience and MS Center, University Hospital Basel and University of Basel, Basel, Switzerland., de Seze J; University Hospital of Strasbourg, Strasbourg, France., Hauser SL; University of California, San Francisco, CA, USA., Overell J; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Koendgen H; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Manfrini M; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Wang Q; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Wolinsky JS; McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA. |
| Source: | European journal of neurology [Eur J Neurol] 2022 Apr; Vol. 29 (4), pp. 1238-1242. Date of Electronic Publication: 2021 May 05. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: England NLM ID: 9506311 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-1331 (Electronic) Linking ISSN: 13515101 NLM ISO Abbreviation: Eur J Neurol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
